Signal Peptide Database - Viruses

 Entry Details
ID   1824
Source Database   UniProtKB/Swiss-Prot
UniProtKB/Swiss-Prot Accession Number   P10033    (Created: 1989-07-01 Updated: 2008-11-25)
UniProtKB/Swiss-Prot Entry Name   SPIKE_FIPV
Protein Name   Spike glycoprotein
Gene   S
Organism Scientific   Feline coronavirus (strain FIPV WSU-79/1146)
Organism Common   FCoV
Lineage   Viruses
  ssRNA positive-strand viruses, no DNA stage
    Nidovirales
      Coronaviridae
        Coronavirus
          Coronavirus group 1
            Coronavirus group 1a
Protein Length [aa]   1452
Protein Mass [Da]   160470
Features  
TypeDescriptionStatusStartEnd
signal peptide      potential   1   19
chain   Spike glycoprotein   potential   20   1452
transmembrane region      potential   1396   1416
topological domain   Extracellular   potential   20   1395
topological domain   Cytoplasmic   potential   1417   1452
glycosylation site   N-linked (GlcNAc...)   potential   29   29
glycosylation site   N-linked (GlcNAc...)   potential   67   67
glycosylation site   N-linked (GlcNAc...)   potential   95   95
glycosylation site   N-linked (GlcNAc...)   potential   155   155
glycosylation site   N-linked (GlcNAc...)   potential   174   174
glycosylation site   N-linked (GlcNAc...)   potential   208   208
glycosylation site   N-linked (GlcNAc...)   potential   234   234
glycosylation site   N-linked (GlcNAc...)   potential   241   241
glycosylation site   N-linked (GlcNAc...)   potential   288   288
glycosylation site   N-linked (GlcNAc...)   potential   337   337
glycosylation site   N-linked (GlcNAc...)   potential   348   348
glycosylation site   N-linked (GlcNAc...)   potential   365   365
glycosylation site   N-linked (GlcNAc...)   potential   408   408
glycosylation site   N-linked (GlcNAc...)   potential   452   452
glycosylation site   N-linked (GlcNAc...)   potential   483   483
glycosylation site   N-linked (GlcNAc...)   potential   519   519
glycosylation site   N-linked (GlcNAc...)   potential   535   535
glycosylation site   N-linked (GlcNAc...)   potential   557   557
glycosylation site   N-linked (GlcNAc...)   potential   565   565
glycosylation site   N-linked (GlcNAc...)   potential   707   707
glycosylation site   N-linked (GlcNAc...)   potential   728   728
glycosylation site   N-linked (GlcNAc...)   potential   783   783
glycosylation site   N-linked (GlcNAc...)   potential   822   822
glycosylation site   N-linked (GlcNAc...)   potential   837   837
glycosylation site   N-linked (GlcNAc...)   potential   843   843
glycosylation site   N-linked (GlcNAc...)   potential   924   924
glycosylation site   N-linked (GlcNAc...)   potential   1077   1077
glycosylation site   N-linked (GlcNAc...)   potential   1203   1203
glycosylation site   N-linked (GlcNAc...)   potential   1297   1297
glycosylation site   N-linked (GlcNAc...)   potential   1314   1314
glycosylation site   N-linked (GlcNAc...)   potential   1327   1327
glycosylation site   N-linked (GlcNAc...)   potential   1339   1339
glycosylation site   N-linked (GlcNAc...)   potential   1344   1344
glycosylation site   N-linked (GlcNAc...)   potential   1361   1361
glycosylation site   N-linked (GlcNAc...)   potential   1374   1374
sequence variant         0   0
sequence variant         0   0
compositionally biased region   Cys-rich      1414   1435
short sequence motif   KxHxx   by similarity   1448   1452
coiled-coil region      potential   1107   1151
coiled-coil region      potential   1341   1383
SP Length   19
 ----+----1----+----2----+----3----+----4----+----5
Signal Peptide MIVLVTCLLLLCSYHTVLS
Sequence MIVLVTCLLLLCSYHTVLSTTNNECIQVNVTQLAGNENLIRDFLFSNFKE
EGSVVVGGYYPTEVWY
NCSRTARTTAFQYFNNIHAFYFVMEAMENSTGNA
RGKPLLFHVHGEPVSVIISAYRDDVQQRPLLKHGLVCITKNRHINYEQFT
SNQW
NSTCTGADRKIPFSVIPTDNGTKIYGLEWNDDFVTAYISGRSYHLN
INTNWFN
NVTLLYSRSSTATWEYSAAYAYQGVSNFTYYKLNNTNGLKTYE
LCEDYEHCTGYATNVFAPTSGGYIPDGFSFNNWFLLT
NSSTFVSGRFVTN
QPLLINCLWPVPSFGVAAQEFCFEGAQFSQCNGVSL
NNTVDVIRFNLNFT
ADVQSGMGATVFSL
NTTGGVILEISCYSDTVSESSSYSYGEIPFGITDGP
RYCYVLY
NGTALKYLGTLPPSVKEIAISKWGHFYINGYNFFSTFPIGCIS
F
NLTTGVSGAFWTIAYTSYTEALVQVENTAIKNVTYCNSHINNIKCSQLT
ANLNNGFYPVASSEVGFV
NKSVVLLPSFFTYTAVNITIDLGMKLSGYGQP
IASTLS
NITLPMQDNNTDVYCIRSNQFSVYVHSTCKSSLWDNIFNQDCTD
VLEATAVIKTGTCPFSFDKLNNYLTFNKFCLSLSPVGANCKFDVAARTRT
NEQVVRSLYVIYEEGDNIVGVPSDNSGLHDLSVLHLDSCTDYNIYGRTGV
GIIRRT
NSTLLSGLYYTSLSGDLLGFKNVSDGVIYSVTPCDVSAQAAVID
GAIVGAMTSINSELLGLTHWTTTPNFYYYSIY
NYTSERTRGTAIDSNDVD
CEPVITYSNIGVCKNGALVFI
NVTHSDGDVQPISTGNVTIPTNFTISVQV
EYMQVYTTPVSIDCARYVCNGNPRCNKLLTQYVSACQTIEQALAMGARLE
NMEVDSMLFVSENALKLASVEAF
NSTENLDPIYKEWPSIGGSWLGGLKDI
LPSHNSKRKYGSAIEDLLFDKVVTSGLGTVDEDYKRCTGGYDIADLVCAQ
YYNGIMVLPGVANADKMTMYTASLAGGITLGALGGGAVAIPFAVAVQARL
NYVALQTDVLNKNQQILANAFNQAIG
NITQAFGKVNDAIHQTSQGLATVA
KALAKV
QDVVNTQGQALSHLTVQLQNNFQAISSSISDIYNRLDELSADAQ
V
DRLITGRLTALNAFVSQTLTRQAEVRASRQLAKDKVNECVRSQSQRFGF
CG
NGTHLFSLANAAPNGMIFFHTVLLPTAYETVTAWSGICASDGDRTFGL
VVKDVQLTLFRNLDDKFYLTPRTMYQPRVATSSDFVQIEGCDVLFV
NATV
IDLPSIIPDYIDI
NQTVQDILENYRPNWTVPEFTLDIFNATYLNLTGEID
DLEFRSEKLHNTTVELAILIDNINNTLVNLEWL
NRIETYVKWPWYVWLLI
GLVVVFCIPLLLF
CCFSTGCCGCIGCLGSCCHSICSRRQFENYEPIEKVH
VH
Original MIVLVTCLLLLCSYHTVLSTTNNECIQVNVTQLAGNENLIRDFLFSNFKE
EGSVVVGGYYPTEVWYNCSRTARTTAFQYFNNIHAFYFVMEAMENSTGNA
RGKPLLFHVHGEPVSVIISAYRDDVQQRPLLKHGLVCITKNRHINYEQFT
SNQWNSTCTGADRKIPFSVIPTDNGTKIYGLEWNDDFVTAYISGRSYHLN
INTNWFNNVTLLYSRSSTATWEYSAAYAYQGVSNFTYYKLNNTNGLKTYE
LCEDYEHCTGYATNVFAPTSGGYIPDGFSFNNWFLLTNSSTFVSGRFVTN
QPLLINCLWPVPSFGVAAQEFCFEGAQFSQCNGVSLNNTVDVIRFNLNFT
ADVQSGMGATVFSLNTTGGVILEISCYSDTVSESSSYSYGEIPFGITDGP
RYCYVLYNGTALKYLGTLPPSVKEIAISKWGHFYINGYNFFSTFPIGCIS
FNLTTGVSGAFWTIAYTSYTEALVQVENTAIKNVTYCNSHINNIKCSQLT
ANLNNGFYPVASSEVGFVNKSVVLLPSFFTYTAVNITIDLGMKLSGYGQP
IASTLSNITLPMQDNNTDVYCIRSNQFSVYVHSTCKSSLWDNIFNQDCTD
VLEATAVIKTGTCPFSFDKLNNYLTFNKFCLSLSPVGANCKFDVAARTRT
NEQVVRSLYVIYEEGDNIVGVPSDNSGLHDLSVLHLDSCTDYNIYGRTGV
GIIRRTNSTLLSGLYYTSLSGDLLGFKNVSDGVIYSVTPCDVSAQAAVID
GAIVGAMTSINSELLGLTHWTTTPNFYYYSIYNYTSERTRGTAIDSNDVD
CEPVITYSNIGVCKNGALVFINVTHSDGDVQPISTGNVTIPTNFTISVQV
EYMQVYTTPVSIDCARYVCNGNPRCNKLLTQYVSACQTIEQALAMGARLE
NMEVDSMLFVSENALKLASVEAFNSTENLDPIYKEWPSIGGSWLGGLKDI
LPSHNSKRKYGSAIEDLLFDKVVTSGLGTVDEDYKRCTGGYDIADLVCAQ
YYNGIMVLPGVANADKMTMYTASLAGGITLGALGGGAVAIPFAVAVQARL
NYVALQTDVLNKNQQILANAFNQAIGNITQAFGKVNDAIHQTSQGLATVA
KALAKVQDVVNTQGQALSHLTVQLQNNFQAISSSISDIYNRLDELSADAQ
VDRLITGRLTALNAFVSQTLTRQAEVRASRQLAKDKVNECVRSQSQRFGF
CGNGTHLFSLANAAPNGMIFFHTVLLPTAYETVTAWSGICASDGDRTFGL
VVKDVQLTLFRNLDDKFYLTPRTMYQPRVATSSDFVQIEGCDVLFVNATV
IDLPSIIPDYIDINQTVQDILENYRPNWTVPEFTLDIFNATYLNLTGEID
DLEFRSEKLHNTTVELAILIDNINNTLVNLEWLNRIETYVKWPWYVWLLI
GLVVVFCIPLLLFCCFSTGCCGCIGCLGSCCHSICSRRQFENYEPIEKVH
VH
 ----+----1----+----2----+----3----+----4----+----5
Hydropathies  
 

© 2007-2017 Dr. Katja Kapp, Kassel & thpr.net e. K., Dresden, Germany, last update 2010-06-11